Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JADE201 in Rheumatoid Arthritis
NCT07533955Phase 1Recruiting
- Sponsor
- Jade Biosciences, Inc.
- Start
- May 2026
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing JADE201 with Placebo (2 arms). Primary endpoint: Safety and Tolerability of Single Ascending Doses at 36 weeks. Started May 2026; status: recruiting.
02
Drugs
JADE201
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07533955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07533955.